Glucagon-Like Peptide-1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Diabetes.
CONCLUSIONS: Adding exenatide to titrated glargine with metformin resulted in similar glycemic control as adding lispro and was well tolerated. These findings support exenatide as a noninsulin addition for patients failing basal insulin.
PMID: 25011946 [PubMed - as supplied by publisher] (Source: Diabetes Care)
Source: Diabetes Care - July 10, 2014 Category: Endocrinology Authors: Diamant M, Nauck MA, Shaginian R, Malone JK, Cleall S, Reaney M, de Vries D, Hoogwerf BJ, MacConell L, Wolffenbuttel BH, for the 4B Study Group Tags: Diabetes Care Source Type: research
Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro.
CONCLUSIONS: Weekly albiglutide is a simpler therapeutic option than thrice-daily lispro for advancing basal insulin glargine therapy, resulting in comparable HbA1c reduction with weight loss and lower hypoglycemia risk.
PMID: 24898300 [PubMed - as supplied by publisher] (Source: Diabetes Care)
Source: Diabetes Care - June 4, 2014 Category: Endocrinology Authors: Rosenstock J, Fonseca VA, Gross JL, Ratner RE, Ahrén B, Chow FC, Yang F, Miller D, Johnson SL, Stewart MW, Leiter LA, for the Harmony-6 Study Group Tags: Diabetes Care Source Type: research
Subcutaneous Injection of Hyaluronidase with Recombinant Human Insulin Compared with Insulin Lispro in Type 1 Diabetes
(Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - May 19, 2014 Category: Endocrinology Authors: Satish K. Garg, John B. Buse, Jay S. Skyler, Daniel E. Vaughn, Douglas B. Muchmore Tags: ORIGINAL PAPER Source Type: research
Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial
ConclusionsIn patients with type 2 diabetes inadequately controlled on once‐daily basal insulin glargine and metformin and/or pioglitazone, intensification with LM25 was superior to a basal–prandial approach in terms of reduction in HbA1c after 24 weeks and did not increase hypoglycaemia episodes. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - May 6, 2014 Category: Endocrinology Authors: F. J. Tinahones, J. L. Gross, A. Onaca, S. Cleall, A. Rodríguez Tags: ORIGINAL ARTICLE Source Type: research
AUTONOMY: The first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes.
ConclusionsPrandial insulin lispro can effectively and safely be initiated, by either of 2 self-titrated algorithms, in a variety of practice settings.
PMID: 24742662 [PubMed - as supplied by publisher] (Source: Diabetes Care)
Source: Diabetes Care - April 17, 2014 Category: Endocrinology Authors: Edelman SV, Liu R, Johnson J, Glass LC Tags: Diabetes Care Source Type: research
Glycemic Control after 6 Days of Insulin Pump Reservoir Use in Type 1 Diabetes: Results of Double‐Blind and Open‐Label Cross‐Over Trials of Insulin Lispro and Insulin Aspart
ConclusionWhile the mean blood glucose on Day 6 of Lis6D did not meet non‐inferiority, the overall daily mean blood glucose was not different, with a decreased rate of hypoglycemia with Lis. (Source: Journal of Diabetes)
Source: Journal of Diabetes - April 15, 2014 Category: Endocrinology Authors: William V. Tamborlane, Eric Renard, R. Paul Wadwa, Thomas Blevins, Scott J. Jacober, Rong Liu, Deborah N. D'Souza, Tina M. Rees Tags: Original Article Source Type: research
Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial
ConclusionsIn patients with type 2 diabetes inadequately controlled on once‐daily basal insulin glargine and metformin and/or pioglitazone, intensification with LM25 was superior to a basal‐prandial approach in terms of reduction in HbA1c after 24 weeks and did not increase hypoglycemia episodes. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - April 1, 2014 Category: Endocrinology Authors: Francisco J. Tinahones, Jorge L. Gross, Adriana Onaca, Simon Cleall, Angel Rodríguez Tags: ORIGINAL PAPER Source Type: research
Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open‐label trial
ConclusionsILPS was non‐inferior to glargine for HbA1c change over 24 weeks, but was associated with less HbA1c reduction and more nocturnal hypoglycaemia. Treat‐to‐target basal insulin therapy improves glycaemic control and is associated with minimal weight gain when added to OAMs and exenatide BID for suboptimally controlled T2D. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - December 29, 2013 Category: Endocrinology Authors: R. F. Arakaki, T. C. Blevins, J. K. Wise, D. R. Liljenquist, H. H. Jiang, J. G. Jacobson, S. A. Martin, J. A. Jackson Tags: ORIGINAL ARTICLE Source Type: research
Comparison of Insulin Lispro Protamine Suspension versus Insulin Glargine Once Daily Added to Oral Antihyperglycaemic Medications and Exenatide in Type 2 Diabetes: a Prospective Randomised Open‐Label Trial
ConclusionsILPS was non‐inferior to glargine for HbA1c change over 24 weeks, but was associated with less HbA1c reduction and more nocturnal hypoglycaemia. Treat‐to‐target basal insulin therapy improves glycaemic control and is associated with minimal weight gain when added to OAMs and exenatide BID for suboptimally‐controlled T2D. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - December 3, 2013 Category: Endocrinology Authors: Richard F. Arakaki, Thomas C. Blevins, Jonathan K. Wise, David R. Liljenquist, Honghua H. Jiang, Jennie G. Jacobson, Sherry A. Martin, Jeffrey A. Jackson Tags: Original Paper Source Type: research
Pre-Clinical in Vitro and in Vivo Evidence for Plausible Mechanisms Underlying the Risk of Cancer Associated with Insulin and Insulin Analogues.
Conclusion: In general many studies on pre-clinical in vitro and in vivo evidence for plausible mechanisms underlying the risk of cancer associated with insulin and insulin analogues exist. However, the level of evidence or a causal association between insulin and insulin analogues and cancer is low.
PMID: 24215309 [PubMed - as supplied by publisher] (Source: Current Drug Safety)
Source: Current Drug Safety - November 7, 2013 Category: Drugs & Pharmacology Authors: Vestergaard P, Starup-Linde J Tags: Curr Drug Saf Source Type: research
Effect of gender on treatment outcomes in type 2 diabetes mellitus
Abstract: Aim: To evaluate the effect of gender on clinical outcomes in people with type 2 diabetes mellitus (T2DM) receiving antidiabetes therapy.Methods: This is a pooled analysis from nine similarly designed phase 3 and 4 randomized, controlled studies evaluating insulin glargine and an active comparator (NPH insulin, insulin lispro, premixed insulin, oral antidiabetes drugs, dietary intervention) in adults with T2DM. Impact of gender on outcomes including HbA1c, fasting plasma glucose (FPG), weight-adjusted insulin dose, and hypoglycemia incidence was evaluated after 24 weeks of treatment.Results: Overall, 1651 male an...
Source: Diabetes Research and Clinical Practice - November 4, 2013 Category: Endocrinology Authors: J.B. McGill, A. Vlajnic, P.G. Knutsen, C. Recklein, M. Rimler, S.J. Fisher Tags: Critical Care and Education Source Type: research
Contrasting Weight Changes with LY2605541, a Novel Long‐Acting Insulin, and Insulin Glargine Despite Similar Improved Glycaemic Control in T1DM and T2DM
ConclusionIn two Phase 2 trials, improved glycaemic control with long‐acting basal insulin analogue LY2605541 is associated with weight loss in previously insulin‐treated patients. This weight change is independent of baseline BMI or hypoglycaemia. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - October 8, 2013 Category: Endocrinology Authors: Scott J. Jacober, Julio Rosenstock, Richard M. Bergenstal, Melvin J. Prince, Yongming Qu, John M. Beals Tags: Original Article Source Type: research
Will the next generation of basal insulins offer clinical advantages?
Abstract
The 21st century has seen the arrival of several insulin analogue products and the refinement of insulin regimens, with widespread advocacy of continuous titration algorithms and earlier initiation of supplementary insulin therapy (predominantly using basal insulins) in type 2 diabetes. Nevertheless, many insulin‐treated diabetes patients remain in poor glycaemic control. This might reflect insufficient titration effort or lax adherence, but these issues could in some cases result from concerns about hypoglycaemia. Certainly there is scope for improving the pharmacokinetic/pharmacodynamic profile of basal insuli...
Source: Diabetes, Obesity and Metabolism - October 4, 2013 Category: Endocrinology Authors: Alan J. Garber Tags: Unsolicited Review article Source Type: research
Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes.
CONCLUSIONS: In our evaluation of older patients from a larger trial, LM75/25 appeared to provide longer durability of glycemic control, as well as a greater number of patients maintaining HbA1c goal versus GL.
PMID: 24092662 [PubMed - as supplied by publisher] (Source: Aging Clinical and Experimental Research)
Source: Aging Clinical and Experimental Research - October 3, 2013 Category: Geriatrics Authors: Jovanovič L, Peters AL, Jiang HH, Hardin DS Tags: Aging Clin Exp Res Source Type: research
